Edge 'Devastated' By Phase III Failure of EG-1962, Set To Downsize
Company announces plans for layoffs after Phase III NEWTON 2 study of EG-1962 for subarachnoid hemorrhage goes up in smoke.
You may also be interested in...
Edge Therapeutics Inc. reported on Feb. 19 during the International Stroke Conference (ISC) in Los Angeles on that EG-1962 cut 3.5 days from time spent in the intensive care unit (ICU) and doubled the likelihood of favorable outcomes for patients with aneurysmal subarachnoid hemorrhage (aSAH).
Nymalize, an oral formulation of brain hemorrhage treatment nimodipine, aims to minimize serious risks associated with incorrect administration of older forms of the drug.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.